RPRX - Royalty Pharma plc
IEX Last Trade
25.28
0 0%
Share volume: 48,170
Last Updated: Thu 26 Dec 2024 08:30:23 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
1.30%
PREVIOUS CLOSE
CHG
CHG%
$25.28
0.00
0.00%
Fundamental analysis
50%
Profitability
40%
Dept financing
44%
Liquidity
75%
Performance
55%
Performance
5 Days
-0.08%
1 Month
-4.03%
3 Months
-10.50%
6 Months
-5.08%
1 Year
-7.38%
2 Year
-36.03%
Key data
Stock price
$25.28
DAY RANGE
$25.17 - $25.46
52 WEEK RANGE
$24.48 - $31.66
52 WEEK CHANGE
-$9.76
DIVIDEND
$0.21
EX-DIVIDEND DATE
08/16/2024
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO: Pablo G. Legorreta
Region: US
Website: royaltypharma.com
Employees: 80
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: royaltypharma.com
Employees: 80
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Royalty Pharma plc was founded in 1996 and is based in New York, New York. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates.
Recent news